This mistake is more common than it should be. And it's not really the patient's fault.

The long road to diagnosis

Most people with EoE spend years in the wrong diagnostic lane. The symptoms, difficulty swallowing, a feeling that food is getting stuck, the occasional alarming episode of a food bolus that won't move, are easy to attribute to reflux, anxiety, or simply eating too fast. Many patients receive a GERD diagnosis and are told to try a PPI. Some improve for a while. Others don't, but assume the problem is lifestyle rather than pathology.

EoE cannot be diagnosed from symptoms alone. It requires endoscopy with biopsy, and the biopsy needs to demonstrate eosinophilic infiltration of the oesophageal lining at a threshold that distinguishes it from other conditions. This means the patient needs a gastroenterologist willing to scope and specifically look for it, which often doesn't happen until something more acute, a food bolus obstruction managed in emergency, forces the question.

By the time a diagnosis arrives, many patients have quietly restructured their entire relationship with food: cutting everything into small pieces, avoiding bread and meat, sitting near the door at restaurants. The adaptation is so gradual they've often stopped mentioning it to doctors.

Why the medication is a formulation problem

The most commonly used treatments for EoE in Australia are swallowed topical corticosteroids. Fluticasone propionate, the same drug in many asthma inhalers, is actuated into the mouth and swallowed without inhaling. Budesonide is typically compounded into a viscous slurry with sucralose syrup. Both are respiratory or dermatological drugs repurposed for a gastroenterological condition, and the formulation detail matters as much as the drug itself.

For these medications to work, they need to coat the oesophagus. That requires viscosity and time. A budesonide preparation that's too thin passes through too quickly. A patient who rinses or drinks anything in the thirty minutes after administration loses much of the intended contact time. Instructions that don't make these requirements explicit leave patients using the medication incorrectly, without knowing it, for months or longer.

The fluticasone situation is particularly prone to error. The device is designed for inhalation. Every piece of labelling, every instinct the patient brings to it, points toward the lungs. Without explicit instruction from both the gastroenterologist and the dispensing pharmacist, the wrong technique is almost predictable.

Compounding pharmacies play a specific role here. Viscous budesonide for EoE needs to be prepared to a formulation that gives it the right consistency and stability. A standard pharmacy that prepares it without understanding the clinical purpose, or dispenses it without explaining what the patient actually needs to do, isn't filling this prescription correctly in any meaningful sense.

Layering an elimination diet on top 

Medication alone isn't always sufficient, and many patients with EoE also manage an elimination diet. The approach typically involves removing common triggers, often beginning with milk, wheat, eggs, and soy, then reintroducing them one at a time while monitoring symptoms and, in some protocols, repeating endoscopy to assess oesophageal response.

In practice, this is a significant undertaking. The restrictions are demanding, the reintroduction phase is slow, and the only reliable way to confirm whether a given food is a trigger is a repeat scope. Patients managing this alongside a compounded swallowed steroid are carrying a substantial treatment burden, and adherence on both fronts degrades quietly over time in ways that aren't always visible in a clinic appointment.

Dietitian involvement makes a real difference, and most gastroenterology guidelines for EoE recommend it. But access isn't uniform, and patients don't always know to ask.

When steroids and diet aren't enough 

For patients whose EoE doesn't respond adequately to swallowed steroids and dietary management, dupilumab offers a different mechanism. It targets the IL-4 and IL-13 signalling pathways involved in the type 2 inflammatory response that drives EoE, and it's approved in Australia for this indication.

For patients who've spent years cycling through elimination diets and steroid regimens without adequate response, it's a meaningful development. But starting a biologic carries its own education load: correct injection technique, cold chain storage, and understanding what a clinical response should look like and over what timeframe. Patients who already use dupilumab for atopic dermatitis or asthma, conditions that frequently coexist with EoE, may be familiar with the process. Those starting it for the first time in this context need more than a sharps bin and a product leaflet.

How Ace can help

The gap in EoE care often isn't the drug. It's what happens between the prescription being written and the patient using the medication correctly. A pharmacy that understands swallowed-steroid formulation, compounds budesonide to a clinically appropriate viscosity, and counsels patients explicitly on administration technique is addressing something that standard dispensing doesn't cover.

Ace works with gastroenterologists managing patients with EoE, including those on compounded topical steroids and those moving to biologic therapy. If you've recently been diagnosed, or if you've been managing EoE for a while without confidence that your formulation or technique is right, our pharmacists can help.

Visit https://acepharmacy.com.au/ to get in touch.

This article is for general information only and is not a substitute for advice from your treating gastroenterologist or specialist. EoE management should be guided by a clinician with experience in the condition.